Psoralen Induced Liver Injury by Attenuating Liver Regenerative Capability

Zhou Wang, Xi Chen, Guolin Zhao, Dengqiu Xu, Zhenzhou Jiang, Luyong Zhang, Tao WangFrontiers in Pharmacology 2018 · DOI

TL;DR

This study reveals that psoralen, a key component of the traditional Chinese medicine Fructus Psoraleae (FP), can induce mild liver injury by disrupting liver regeneration and cell cycle progression. The findings highlight the role of psoralen in inhibiting the mTOR signaling pathway and causing mitochondrial damage, offering insights into reducing FP-related hepatotoxicity.

What Problem Does This Paper Address?

Fructus Psoraleae (FP) is a widely used traditional Chinese medicine for various ailments. However, clinical reports have linked FP use to severe liver injury, raising concerns about its hepatotoxicity. While psoralen is a major active compound in FP, the specific mechanisms by which it might cause liver damage have not been fully elucidated. This paper aims to investigate the hepatotoxicity of psoralen and unravel the underlying molecular mechanisms, particularly focusing on its impact on liver regeneration and cellular processes.

Methods

The researchers employed a multi-faceted approach:

  • In vivo studies:
    • Acute oral toxicity: Determined the median lethal dose (LD50) of psoralen in ICR mice.
  • Hepatotoxicity assessment: Administered psoralen to C57BL/6 mice at different doses and analyzed liver/body weight ratios, serum liver enzymes (ALT, AST), total protein (TP), albumin (ALB), total bile acids (TBA), total bilirubin (TBIL), and performed histological examination of liver tissues.
  • Liver regeneration model: Utilized a 2/3 partial hepatectomy (PHx) model in mice to assess the impact of psoralen on liver regeneration. This involved measuring liver regeneration rates, body weight changes, and performing immunohistochemistry for proliferation markers (Ki-67, PCNA).
  • Molecular analysis: Conducted Western blotting to examine the expression levels of cell cycle-related proteins (cyclin D1, cyclin E1, cyclin A2, CDK1, p27) and mTOR signaling pathway components (AMPK, AKT, mTOR, p70S6K, 4E-BP1) in both liver tissues and cell lines. Real-time qPCR was used to analyze mRNA expression of inflammatory cytokines (IL-6, TNF-α, HGF) and mitochondrial genes (COX-1, TFAM).
  • Mitochondrial damage assessment: Evaluated ATP content in liver mitochondria and performed transmission electron microscopy to observe mitochondrial morphology.
  • In vitro studies:
    • Cell viability assays: Used MTT and LDH release assays to assess the cytotoxicity of psoralen on human liver cell lines (L02 and HepG2).
  • Cell cycle analysis: Employed flow cytometry with propidium iodide (PI) staining to determine the effect of psoralen on cell cycle distribution and apoptosis (Annexin V-FITC/PI staining).
  • Mechanism exploration: Investigated the role of the mTOR pathway by using MHY, an mTOR activator, in combination with psoralen to observe its effect on S-phase arrest and cell morphology.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Psoralen's Dual Role: Psoralen, while a therapeutic component, also exhibits hepatotoxic potential, especially at higher doses or in compromised liver states.
  • Cell Cycle Arrest as a Key Mechanism: The primary mechanism of psoralen's toxicity appears to be the induction of S-phase arrest in liver cells, rather than direct cell death. This arrest disrupts normal cell proliferation.
  • Impaired Liver Regeneration: Psoralen significantly delays liver regeneration in a partial hepatectomy model, suggesting that its interference with cell cycle progression hinders the liver's ability to repair itself.
  • mTOR Pathway Inhibition: The study implicates the inhibition of the mTOR signaling pathway as a crucial factor in psoralen-induced S-phase arrest and subsequent hepatotoxicity.
  • Mitochondrial Dysfunction: Psoralen also leads to mitochondrial damage, evidenced by reduced ATP production and altered mitochondrial morphology, contributing to cellular stress.
  • PHx Model Sensitivity: The partial hepatectomy (PHx) model proved to be more sensitive in detecting psoralen's hepatotoxicity, highlighting its utility for evaluating drugs with mild toxic effects.

Key Results

  • The acute oral LD50 of psoralen in mice was determined to be 1,673 mg/kg.
  • Administration of 400 mg/kg and 800 mg/kg psoralen to C57BL/6 mice for 24 hours caused mild liver injury, indicated by elevated ALT and AST, and decreased TP and ALB levels. Histological examination revealed hepatocellular edema.
  • In vitro, psoralen inhibited L02 cell viability by inducing S-phase arrest, with minimal induction of apoptosis.
  • Psoralen treatment led to the upregulation of cyclin E1 and p27 protein levels in both L02 cells and mouse livers.
  • In the PHx mouse model, psoralen significantly delayed liver regeneration, evidenced by reduced regeneration rates and fewer proliferating hepatocytes.
  • Psoralen inhibited the mTOR signaling pathway by activating AMPK and inhibiting AKT, mTOR, p70S6K, and 4E-BP1.
  • MHY, an mTOR activator, partially reversed psoralen-induced S-phase arrest in L02 cells.
  • Psoralen treatment reduced intracellular ATP content and caused significant mitochondrial damage in L02 cells and mouse liver mitochondria.

Limitations and Future Work

  • Mechanism of HepG2 Inhibition: While psoralen inhibited HepG2 cell viability, the specific mechanism was not fully elucidated in this study.
  • Cause vs. Result of Mitochondrial Damage: The study indicates psoralen induces mitochondrial damage, but it remains unclear whether this is a cause or a consequence of hepatotoxicity, requiring further investigation.
  • Precise Cyclin/CDK Interactions: The exact molecular mechanisms by which psoralen-induced overexpression of cyclin E1 and p27 leads to S-phase arrest require further detailed study, as there are ongoing debates regarding the precise roles of different cyclin and CDK types.
  • mTOR Pathway Specificity: While the study demonstrates the involvement of the mTOR pathway, further research is needed to clarify the specific interactions between mTOR signaling, cell cycle progression, and the regulation of cyclin E1 and p27.
  • Clinical Relevance of High Doses: The doses of psoralen used in the animal studies were significantly higher than typical human therapeutic doses. While the study acknowledges this, further research could explore the effects of lower, more clinically relevant doses.

The authors suggest further investigation into the precise interactions within the mTOR signaling pathway and its relationship with cyclin E1 and p27 to fully understand the molecular mechanisms of psoralen-induced cycle arrest.

Summary updated

Abstract

Psoralen is a major component of the common traditional Chinese medicine <i>Fructus Psoraleae</i> (FP). In this study, we focused on psoralen to explore FP-induced hepatotoxicity and the underlying mechanisms. The acute oral median lethal dose of psoralen in ICR mice was determined to be 1,673 mg/kg. C57BL/6 mice were administered psoralen intragastrically at doses of 400 mg/kg or 800 mg/kg, and were sacrificed 24 h after treatment. Changes in various hepatotoxicity indicators demonstrated that psoralen can cause mild liver injury in mice. Psoralen inhibited the viability of normal human liver L02 cells <i>in vitro</i> by inducing S-phase arrest. In addition, psoralen in both the mouse livers and L02 cells upregulated cyclin E1 and p27 protein levels. The 2/3 partial hepatectomy mouse model was used to further explore the effects of psoralen on the liver regeneration and hepatocellular cycle arrest <i>in vivo</i>. The results showed that the decrease of liver regenerative and self-healing capabilities induced by hepatocellular cycle arrest may play an important role in the hepatotoxicity of psoralen. The further mechanism researches indicated that psoralen-induced hepatotoxicity was associated with inhibition of mTOR signalling pathway and mitochondrial injury; furthermore, MHY, an mTOR activator, partly alleviated the inhibition of mTOR and S-phase cycle arrest induced by psoralen in L02 cells. In conclusion, in this study we showed for the first time, that psoralen significantly induced liver injury in mice; the decrease of liver regenerative and compensatory capabilities induced by hepatocellular cycle arrest may play an important role in the progression of hepatotoxicity associated with the upregulation of cyclin E1 and p27, as well as the inhibition of mTOR signalling and mitochondrial injury. Our findings may contribute to the reduction of hepatotoxicity risk induced by <i>Fructus Psoraleae.</i>
BibTeX
@inproceedings{wang2018psoralen,
  author = {Zhou Wang and Xi Chen and Guolin Zhao and Dengqiu Xu and Zhenzhou Jiang and Luyong Zhang and Tao Wang},
  title = {{Psoralen Induced Liver Injury by Attenuating Liver Regenerative Capability}},
  booktitle = {Frontiers in Pharmacology},
  year = {2018},
  doi = {10.3389/fphar.2018.01179},
}
Figure